| 495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18. 2 (CLDN18. 2)-targeted antibody-drug conjugate, in second-or later-line (2L+) advanced gastric … K Shitara, YY Janjigian, E Elimova, J Zhang, MH Chen, E Smyth, J Lee, ... Annals of Oncology 35, S196-S197, 2024 | | 2024 |
| 465P Timing of first-line palliative systemic therapy in metastatic Esophagogastric cancer (mEGC): A European Delphi study D Kamp, AM May, A Adenis, AC Marques, S Derks, F Defelice, NF Dovnik, ... Annals of Oncology 35, S186-S187, 2024 | | 2024 |
| 499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN … E Smyth, D Griffiths, K Cozens, C Hurt, R Waugh, R Turkington, K Foley, ... Annals of Oncology 35, S199, 2024 | | 2024 |
| Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation JR O'Neill, MY Mayordomo, G Mitulović, S Al Shboul, G Bedran, J Faktor, ... Molecular & Cellular Proteomics 23 (6), 2024 | 1 | 2024 |
| Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies A Hall, SR Brown, NB Mettu, PC Miller, EC Smyth, AB Nixon American Society of Clinical Oncology Educational Book 44 (3), e433640, 2024 | | 2024 |
| CO62 Clinical Outcomes of Second-Line (2L) Treatments (TXS) in Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): A Systematic Literature Review (SLR) MA Novis de Figueiredo, E Smyth, CJ Coaquira, T Chaudhary, E Finn, ... Value in Health 27 (6), S28, 2024 | | 2024 |
| CO17 Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Immuno-Oncology (IO) for First-Line (1L) Esophageal Squamous Cell Carcinoma (ESCC) in Adult … E Smyth, A Sibiga, CJ Coaquira, K Szafranski, S Craigie, L Zhan Value in Health 27 (6), S19, 2024 | | 2024 |
| CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18. 2-expressing advanced solid tumors. AG Raufi, L Goyal, E Smyth, P Szekeres, M Petrone, R Hobson, K Thress, ... Journal of Clinical Oncology 42 (16_suppl), TPS3163-TPS3163, 2024 | | 2024 |
| Validation of PD-L1 as a predictive biomarker of response in operable gastroesophageal adenocarcinoma: A meta-analysis and meta-regression of neoadjuvant chemoimmunotherapy trials. A Cammarota, SK Kamarajah, S Markar, EC Smyth Journal of Clinical Oncology 42 (16_suppl), 4065-4065, 2024 | | 2024 |
| Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape CA Cella, D Ciardiello, L Gervaso, H van Laarhoven, L Nezi, C Catozzi, ... ESMO Gastrointestinal Oncology 4, 100048, 2024 | 1 | 2024 |
| European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4) TE Kroese, S Bronzwaer, PSN van Rossum, SF Schoppman, ... European Journal of Cancer 204, 114062, 2024 | | 2024 |
| Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer R Sundar, EC Smyth The Lancet Gastroenterology & Hepatology 9 (6), 495-497, 2024 | 2 | 2024 |
| United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023 ME Booth, HA Clements, J Helbrow, MA Baxter, CW Bleaney, ... Clinical Oncology, 2024 | | 2024 |
| Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled … A Raimondi, YW Kim, WK Kang, RE Langley, YY Choi, KM Kim, ... European Journal of Cancer 203, 114043, 2024 | | 2024 |
| Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023 Y Kitagawa, S Matsuda, T Gotoda, K Kato, B Wijnhoven, F Lordick, ... Gastric Cancer 27 (3), 401-425, 2024 | 3 | 2024 |
| Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal … E Cartwright, S Slater, C Saffery, A Tran, F Turkes, G Smith, M Aresu, ... ESMO open 9 (4), 102971, 2024 | | 2024 |
| Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group C Fulgenzi, I Garajová, M Moehler, MP Lutz, E Smyth, L Rimassa, ... ESMO Gastrointestinal Oncology 3, 100039, 2024 | | 2024 |
| Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy EC Smyth, D Watson, MP Castro, B Nutzinger, S Kapoor, S Rajagopalan, ... ESMO Gastrointestinal Oncology 3, 100010, 2024 | | 2024 |
| A wind of change in upper gastrointestinal cancers: updates from ESMO 2023 A Cammarota, AR Siebenhüner, MA Maqueda, T Fleitas-Kanonnikoff, ... ESMO Gastrointestinal Oncology 3, 100035, 2024 | | 2024 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer K Shitara, T Fleitas, H Kawakami, G Curigliano, Y Narita, F Wang, ... ESMO open 9 (2), 102226, 2024 | 3 | 2024 |
